The Claim
In patients with Graves' disease, the cytokines IL-17a, IL-22, IL-23, and IL-10 are positively correlated with each other, but show no significant correlation with anti-TSHR autoantibodies.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with Graves' disease, certain inflammatory signaling molecules (IL-17a, IL-22, IL-23, and IL-10) tend to increase or decrease together, but their levels do not relate to the levels of autoantibodies that target the thyroid-stimulating hormone receptor.
See the scientific wording
In patients with Graves’ disease, Th17-associated cytokines IL-17a, IL-22, IL-23, and IL-10 are positively correlated with each other, indicating coordinated expression of this inflammatory pathway, but not with anti-TSHR autoantibodies, suggesting that T-cell-driven inflammation may operate independently of B-cell-mediated autoantibody production.
What the research says
1 studyStudy: Plasma levels of Th17‐associated cytokines and selenium status in autoimmune thyroid diseases
The study found that certain inflammation-related molecules in Graves' disease patients tend to rise and fall together, which matches the claim. It didn't check the antibody levels, so we can't say for sure if they're linked or not — but that doesn't break the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.